💡Pawel, from Remedy’s Post
10mo
Boots UK vs Holland & Barrett: A new Balance of Power in Nutraceutical Retail The demerger of Boots from Walgreens is more than a corporate reshuffle. It reshapes the competitive landscape in health and wellness retail, and nowhere is the impact more visible than in its rivalry with Holland & Barrett. Boots, free and faster Until now, Boots has been constrained by Walgreens’s global agenda. The spin-off gives it freedom to act with speed. That matters in nutraceuticals. Categories move quickly. Collagen peptides, probiotics, nootropics and adaptogens can rise from niche to mainstream in a matter of months. Boots will now be able to test, launch and scale these formats without the drag of a US-centric parent. Holland & Barrett’s edge at risk H&B has built its brand on being the early adopter. CBD before it was mainstream. Collagen and beauty from within when others ignored it. Probiotics and digestive health long before the gut microbiome was a headline. The risk now is that Boots can match this agility, while leveraging its wider footprint and pharmacy credibility. Scale and trust H&B operates around 1,600 stores. Boots has close to 4,000. That scale translates into bargaining power with suppliers, lower cost per unit, and stronger visibility for private label. On top of that, Boots carries the pharmacy halo. Consumers trust Boots not just for cosmetics or vitamins, but for medical advice and prescriptions. For a new nutraceutical category, being on a Boots shelf signals validation in a way few other retailers can. Pressure on margins and formats H&B has relied heavily on private label margins. Boots can now use its scale to enter the same categories with equal or greater force. Expect Boots-branded probiotics, gummies and multivitamins to compete directly on price with H&B’s core ranges. This creates margin pressure that H&B will need to offset with differentiation, premium partnerships, or exclusive formats. International advantage Boots is doubling down on international markets such as Thailand, Germany, Mexico and Ireland. Each of these regions has strong growth in supplements. Thailand for beauty-from-within, Germany for regulated high-science nutraceuticals, Mexico for immunity and energy, and Ireland for functional wellness start-ups. H&B has almost no footprint in these regions. That creates a global asymmetry. Boots can leverage its network to launch products with international reach. For nutraceutical suppliers and CDMOs, this rivalry matters. A more agile Boots means faster routes to market, larger orders, and higher consumer trust. A pressured H&B means a need for innovation, exclusivity, and premium science to stay relevant. Together, they will accelerate category growth, drive demand for new dosage forms, and set the retail agenda for supplements in Europe and beyond.
More from this author
Explore content categories